Adeno-Associated Virus Variant Capsids with Improved Lung Tropism and Uses Thereof
The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV capsid protein and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.
1 . A variant adeno-associated virus (AAV) capsid protein comprising a peptide insertion relative to a corresponding parental AAV capsid protein, wherein the peptide insertion comprises an amino acid sequence selected from DNTVTRS (SEQ ID NO:14), SNSVQSI (SEQ ID NO: 15), and NSTRHTD (SEQ ID NO:16).
2 . The variant AAV capsid protein according to claim 1 , wherein the insertion site is located within the GH-loop of the capsid protein.
3 - 4 . (canceled)
5 . The variant AAV capsid protein according to claim 2 , wherein the peptide insertion comprises an amino acid sequence selected from LADNTVTRSA (SEQ ID NO: 42), LASNSVQSIA (SEQ ID NO:43), and LANSTRHTDA (SEQ ID NO:44).
6 - 10 . (canceled)
11 . The variant AAV capsid protein according to claim 1 , wherein the AAV capsid protein comprises the amino acid sequence set forth in any one of SEQ ID Nos: 70-72.
12 . The variant AAV capsid according to claim 1 , wherein the capsid protein confers to an infectious rAAV virion an increased infectivity of a lung cell compared to the infectivity of the lung cell by an AAV virion comprising a wild-type AAV capsid protein.
13 . (canceled)
14 . An isolated nucleic acid comprising a nucleotide sequence that encodes a variant AAV capsid protein according to claim 1 .
15 . An infectious recombinant AAV (rAAV) virion comprising a variant AAV capsid protein according to claim 1 .
16 . The rAAV virion according to claim 15 further comprising a heterologous nucleic acid comprising a nucleotide sequence encoding one or more gene products, wherein the nucleotide sequence encoding one or more gene products is operably linked to an expression control sequence.
17 - 20 . (canceled)
21 . The rAAV according to claim 16 , wherein the heterologous nucleic acid comprises a nucleotide sequence encoding CFTR or a biologically active portion thereof.
22 . A host cell comprising the rAAV according to claim 1 .
23 . A pharmaceutical composition comprising the rAAV according to claim 16 and a pharmaceutically acceptable carrier.
24 . A method of delivering a heterologous nucleic acid to a lung cell comprising contacting the lung cell with an rAAV virion comprising (i) a variant capsid protein comprising a peptide insertion selected from the group consisting of HDITKNI (SEQ ID NO:12), NQDYTKT (SEQ ID NO:13), DNTVTRS (SEQ ID NO:14), SNSVQSI (SEQ ID NO:15), NSTRHTD (SEQ ID NO: 16), TNRTSPD (SEQ ID NO:17), LAHDITKNIA (SEQ ID NO:40), LANQDYTKTA (SEQ ID NO:41), LADNTVTRSA (SEQ ID NO:42), LASNSVQSIA (SEQ ID NO:43), LANSTRHTDA (SEQ ID NO:44), LATNRTSPDA (SEQ ID NO:45) and (ii) a heterologous nucleic acid comprising a nucleotide sequence encoding one or more gene products, preferably wherein the rAAV virion is administered to a mammalian subject by pulmonary, endobronchial, intranasal, intratracheal and/or intrabronchial administration.
25 . (canceled)
26 . The method according to claim 24 , wherein the peptide insertion comprises an amino acid sequence selected from LAHDITKNIA (SEQ ID NO:40), LANQDYTKTA (SEQ ID NO:41), LADNTVTRSA (SEQ ID NO:42), LASNSVQSIA (SEQ ID NO: 43), LANSTRHTDA (SEQ ID NO:44), LATNRTSPDA (SEQ ID NO:45).
27 - 31 . (canceled)
32 . The method according to claim 24 , wherein the variant AAV capsid protein comprises or consists of the amino acid sequence set forth in any one of SEQ ID Nos: 70-72.
33 . (canceled)
34 . A method for treating a pulmonary disease comprising administering to a subject in need thereof a therapeutically effective amount of an rAAV virion comprising (i) a variant capsid protein comprising a peptide insertion selected from the group consisting of HDITKNI (SEQ ID NO:12), NQDYTKT (SEQ ID NO:13), DNTVTRS (SEQ ID NO:14), SNSVQSI (SEQ ID NO: 15), NSTRHTD (SEQ ID NO:16), TNRTSPD (SEQ ID NO:17), LAHDITKNIA (SEQ ID NO: 40), LANQDYTKTA (SEQ ID NO:41), LADNTVTRSA (SEQ ID NO:42), LASNSVQSIA (SEQ ID NO:43), LANSTRHTDA (SEQ ID NO:44), LATNRTSPDA (SEQ ID NO: 45) and (ii) a heterologous nucleic acid comprising a nucleotide sequence encoding one or more gene products, or a pharmaceutical composition comprising the rAAV virion and a pharmaceutically acceptable carrier
35 . The method according to claim 34 , wherein the pulmonary disease is selected from chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, pulmonary arterial hypertension, pulmonary hypertension, lung cancer (primary, secondary and metastatic), surfactant deficiency, viral and/or bacterial infection, acute bronchitis, pneumonia (including viral, bacterial, and fungal pneumonia), respiratory tract infections (including pharyngitis, croup, aspergillus, coccidiomycosis, hantavirus pulmonary syndrome, and histoplasmosis), chemical and hypersensitivity pneumonitis, tuberculosis and other mycobacterial infections (including but not limited to Mycobacterium avium ), sarcoidosis, respiratory syncytial virus, pulmonary edema, acute respiratory distress syndrome (ARDS), pneumoconiosis (including black lung disease, asbestosis, and silicosis), interstitial lung disease (including sarcoidosis and autoimmune disease), pulmonary embolism, pleural effusion, pleuritis, mesothelioma, pneumothorax, acute bronchitis, bronchiolitis (including bronchiolitis obliterans), sudden infant death syndrome, sleep apnea, bronchiectasis, bronchopulmonary dysplasia, cryptogenic organizing pneumonia, E-cigarette or vaping use associated lung injury (EVALI), Middle Eastern Respiratory Syndrome (MERS), primary ciliary dyskinesia, Severe Acute Respiratory Syndrome (SARS), alpha-1-antitrypsin deficiency, asthma, interstitial lung disease, and COVID-19 (Coronavirus Disease 2019).
36 - 41 . (canceled)
42 . The method according to claim 35 , wherein the pulmonary disease is cystic fibrosis.
43 . The method according to claim 42 , wherein the heterologous nucleic acid comprises a nucleotide sequence selected from SEQ ID NO:30 or SEQ ID NO:31 or a sequence at least 80%, at least 90%, at least 95% or at least 99% identical thereto.
44 - 45 . (canceled)
46 . An infectious rAAV comprising (i) a variant capsid protein comprising a peptide insertion selected from the group consisting of HDITKNI (SEQ ID NO:12), NQDYTKT (SEQ ID NO: 13), DNTVTRS (SEQ ID NO:14), SNSVQSI (SEQ ID NO:15), NSTRHTD (SEQ ID NO: 16), TNRTSPD (SEQ ID NO:17), LAHDITKNIA (SEQ ID NO:40), LANQDYTKTA (SEQ ID NO: 41), LADNTVTRSA (SEQ ID NO:42), LASNSVQSIA (SEQ ID NO:43), LANSTRHTDA (SEQ ID NO:44), LATNRTSPDA (SEQ ID NO:45) and (ii) a heterologous nucleic acid comprising a nucleotide sequence encoding a gene selected from CFTR or a biologically active portion thereof and SERPINA1 or a biologically active portion thereof.
47 - 49 . (canceled)
50 . A pharmaceutical composition comprising the rAAV according to claim 46 and a pharmaceutically acceptable carrier.
51 - 74 . (canceled)